Atossa Therapeutics (NASDAQ:ATOS) isn't currently generating revenue . In this report, we will consider its annual negative cash flow . We will start by comparing its cash burn with its cash reserves . If that happens, then the length of its cash runway, today, would become a moot point . You might want to take a peek at how much the company is expected to grow .